School of Mathematical Sciences
  1. School of Mathematical Sciences
  2. People
  3. Academic staff
  4. Profiles

Dr Jamie Griffin

Jamie

Lecturer in Applied Probability

Email: j.griffin@qmul.ac.uk
Telephone: +44 (0)20 7882 3648
Room Number: Queens’ Building, Room: CB202
Office Hours: Friday 10.30 - 12.00

Profile

Jamie Griffin is a Lecturer in Applied Probability. His main research area is modelling malaria transmission and control. This research has involved synthesising multiple types of data to be able to make predictions of the impact of interventions in reducing malaria transmission. He has advised policy makers at the WHO on a number of questions covering vaccines and other interventions against malaria. He has also worked on more general problems of statistical inference for infectious diseases.

Before joining Queen Mary, he held an MRC Methodology fellowship at Imperial College. He continues to collaborate with the malaria modelling group there. He also collaborates with a number of staff in the Malaria Centre at the London School of Hygiene and Tropical Medicine.

Research

Publications

  • Sherrard-Smith E, Griffin JT, Winskill P et al. (2018). Systematic review of indoor residual spray efficacy and effectiveness against Plasmodium falciparum in Africa. Nat Commun.
  • Hogan AB, Winskill P, Verity R et al. (2018). Modelling population-level impact to inform target product profiles for childhood malaria vaccines BMC Medicine.
  • Winskill P, Slater HC, Griffin JT et al. (2017). The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study PLoS Medicine.
  • Bretscher MT, Griffin JT, Ghani AC et al. (2017). Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment Malaria Journal.
  • Okell LC, Griffin JT, Roper C (2017). Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa Scientific Reports.
  • Patouillard E, Griffin J, Bhatt S et al. (2017). Global investment targets for malaria control and elimination between 2016 and 2030 BMJ Global Health.
  • Winskill P, Walker PGT, Griffin JT et al. (2017). Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa BMJ Global Health.
  • Churcher TS, Sinden RE, Edwards NJ et al. (2017). Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts PLOS Pathogens.
  • Churcher TS, Lissenden N, Griffin JT et al. (2016). The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. eLife.
  • Griffin JT (2016). Is a reproduction number of one a threshold for Plasmodium falciparum malaria elimination? Malaria Journal.
  • Walker PG, Griffin JT, Ferguson NM et al. (2016). Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. Lancet Glob Health.
  • Marshall JM, Touré M, Ouédraogo AL et al. (2016). Key traveller groups of relevance to spatial malaria transmission: a survey of movement patterns in four sub-Saharan African countries. Malaria Journal.
  • Griffin JT, Bhatt S, Sinka ME et al. (2016). Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. Lancet Infectious Diseases.
  • Penny MA, Verity R, Bever CA et al. (2016). Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet.
  • Slater HC, Griffin JT, Ghani AC et al. (2016). Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J.
  • White MT, Verity R, Griffin JT et al. (2015). Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis.
  • van den Hoogen LL, Griffin JT, Cook J et al. (2015). Serology describes a profile of declining malaria transmission in Farafenni, The Gambia. Malar J.
  • Bhatt S, Weiss DJ, Cameron E et al. (2015). The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature.
  • Cameron E, Battle KE, Bhatt S et al. (2015). Defining the relationship between infection prevalence and clinical incidence of Plasmodium falciparum malaria. Nat Commun.
  • Cairns ME, Walker PGT, Okell LC et al. (2015). Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa. Malar J.
  • Walker PGT, White MT, Griffin JT et al. (2015). Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infect Dis.
  • Griffin JT, Hollingsworth TD, Reyburn H et al. (2015). Gradual acquisition of immunity to severe malaria with increasing exposure. Proc Biol Sci.
  • Griffin JT (2015). The interaction between seasonality and pulsed interventions against malaria in their effects on the reproduction number. PLoS Comput Biol.
  • Okell LC, Cairns M, Griffin JT et al. (2014). Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun.
  • White MT, Griffin JT, Akpogheneta O et al. (2014). Dynamics of the antibody response to Plasmodium falciparum infection in African children. J Infect Dis.
  • Pinsent A, Read JM, Griffin JT et al. (2014). Risk factors for UK Plasmodium falciparum cases. Malar J.
  • White MT, Bejon P, Olotu A et al. (2014). A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med.
  • Griffin JT, Ferguson NM, Ghani AC (2014). Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun.
  • White MT, Griffin JT, Ghani AC (2013). The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum. Malar J.
  • Bousema T, Stevenson J, Baidjoe A et al. (2013). The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial. Trials.
  • Walker PGT, Griffin JT, Cairns M et al. (2013). A model of parity-dependent immunity to placental malaria. Nat Commun.
  • White MT, Bejon P, Olotu A et al. (2013). The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection. PLoS One.
  • Okell LC, Bousema T, Griffin JT et al. (2012). Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun.
  • Bousema T, Griffin JT, Sauerwein RW et al. (2012). Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med.
  • Opatowski L, Fraser C, Griffin J et al. (2011). Transmission characteristics of the 2009 H1N1 influenza pandemic: comparison of 8 Southern hemisphere countries. PLoS Pathog.
  • White MT, Griffin JT, Churcher TS et al. (2011). Modelling the impact of vector control interventions on Anopheles gambiae population dynamics. Parasit Vectors.
  • White MT, Griffin JT, Riley EM et al. (2011). Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proc Biol Sci.
  • Griffin JT, Garske T, Ghani AC et al. (2011). Joint estimation of the basic reproduction number and generation time parameters for infectious disease outbreaks. Biostatistics.
  • Okell LC, Griffin JT, Kleinschmidt I et al. (2011). The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One.
  • Griffin JT, Cairns M, Ghani AC et al. (2010). Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One.
  • Griffin JT, Hollingsworth TD, Okell LC et al. (2010). Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med.
  • Ghani A, Baguelin M, Griffin J et al. (2010). The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom PLoS Currents.
  • Bousema T, Okell L, Shekalaghe S et al. (2010). Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J.
  • White MT, Griffin JT, Drakeley CJ et al. (2010). Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J.
  • Carneiro I, Roca-Feltrer A, Griffin JT et al. (2010). Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One.
  • Stewart L, Gosling R, Griffin J et al. (2009). Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One.
  • Fraser C, Donnelly CA, Cauchemez S et al. (2009). Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings Science.
  • Baggaley RF, Griffin JT, Chapman R et al. (2009). Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS.
  • Ghani AC, Sutherland CJ, Riley EM et al. (2009). Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS One.
  • Corran PH, Cook J, Lynch C et al. (2008). Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J.
  • Gras L, Kesselring AM, Griffin JT et al. (2007). CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr.
  • Griffin JT, Fraser C, Gras L et al. (2006). The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases. Am J Epidemiol.
  • Fidler S, Fraser C, Fox J et al. (2006). Comparative potency of three antiretroviral therapy regimes in primary HIV infection. AIDS.
  • Ghani AC, Donnelly CA, Cox DR et al. (2005). Methods for estimating the case fatality ratio for a novel, emerging infectious disease. Am J Epidemiol.